A global clinical trial based at the University of Pittsburgh School of Medicine (UPSM) is tracking COVID-19 treatment data worldwide and using a machine learning platform to identify the most effective approaches to test on infected patients in its 40-hospital network. Read More
Nearly 1,000 patients with coronavirus in the UK have enrolled in the world’s largest randomized clinical trial of potential COVID-19 treatments. The trial, which has been prioritized and fast-tracked by the UK government, will examine the value of HIV, anti-inflammatory and anti-malarial drugs in fighting the virus. Read More
Sponsors and investigators conducting federally funded research do not need IRB approval for actions taken in response to the threat of COVID-19 as long as those actions are for public health or clinical treatments purposes rather than research, according to a new guidance from the Office for Human Research Protections (OHRP). Read More
Researchers planning trials on the use of convalescent blood plasma to treat COVID-19 must submit an investigational new drug (IND) application, according to a new FDA final guidance that will remain in effect only for the duration of the public health emergency. Read More
Year-over-year global clinical trial enrollment dropped nearly 65 percent per study site in March because of COVID-19, especially in trials focused on endocrine disorders and trials conducted in India. Read More
Clinical trial activity picking back up will likely be dependent on regional factors and sponsors should not expect to see a “day one” for recovery — but they should keep an eye out for certain recovery indicators. Read More
Applications for clinical trials in Belgium can now receive the go-ahead from the government within four days rather than the two to four weeks sponsors previously had to wait. Read More
While some sponsors are pulling back on enrollment and site activation, others are expressing confidence that they can continue their trial activities with adjustments to avoid the risk of COVID-19 exposure. Read More